The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

PMV Pharmaceuticals, Inc. is a precision oncology company, which engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The company was founded by Arnold J. Levine, David Henry Mac, and Thomas E. Shenk in March 2013 and is headquartered in Princeton, NJ.

MultiVir, Inc. is a clinical-stage gene therapy company. It develops a pipeline of novel product candidates for the treatment of multiple oncological indications. The company's gene therapy and oncolytic viral technologies target some of cancer's most fundamental molecular defects. It operates through the following operating segment: business of developing novel cancer treatments. The company product candidates employ genetically engineered adenoviruses, herpes simplex viruses and vaccinia viruses to deliver therapeutic genes into tumors. It currently uses the following three different viral platforms in the development programs: adenovirus, or Ad, herpes simplex virus, or HSV, and vaccinia virus, or VV. MultiVir was founded on November 5, 2009 and is headquartered in Houston, TX.

Myriad Genetics, Inc. is an American molecular diagnostic company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new molecular diagnostic products that assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to a particular drug therapy (personalized medicine), assess a patient's risk of disease progression and disease recurrence (personalized medicine), and measure disease activity. Myriad's discovery of the breast cancer gene, BRCA1 was universally acclaimed as a monumental achievement: "There is no more exciting story in medical science." Myriad was the subject of scrutiny after it became involved in a lawsuit over its patenting practices, which led to the landmark Supreme Court decision Association for Molecular Pathology v. Myriad Genetics, Inc..

ChemoCentryxis a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer. ChemoCentryx focuses on the discovery, development, and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. The company's small molecule product candidates are designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.

CURNA, Inc. was engaged in manufacturing pharmaceutical products. The company was headquartered in Jupiter, FL.

Rhone Poulenc Rorer, a subsidiary of Solvay SA, is a French company that manufactures and distributs pharmaceutical products.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Bionomics Limited engages in the discovery and development of therapeutics for cancer and diseases of the central nervous system in Australia. It has small molecule product development programs in the areas of cancer, anxiety, epilepsy, and multiple sclerosis. The company develops its lead cancer compound, BNC 105, for the treatment of solid tumors, such as breast, lung, colon, and prostate cancers. BNC 105 is a member of the class of compounds, known as vascular disruption agents or VDAs, which shut down the blood supply within a tumor, starving the tumor and preventing its continued growth. The company has commercial partnerships with Genmab A/S; Athena Diagnostics; Laboratory Corporation of America; and Genetic Technologies, Ltd. Bionomics Limited was founded in 1999 and is based in Thebarton, Australia.

The Max Planck Society for the Advancement of Science (German: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.; abbreviated MPG) is a non-governmental and non-profit association of Research Institutes publicly funded by the federal and the state governments of Germany. Additionally, the Max Planck Society and its Institutes receive third party funding from public and private contributions and from the European Union. The world leading organization is named in honor of its former president, theoretical physicist Max Planck. The 86 Institutes and Research Facilities of the Max Planck Society (as of 2020) conduct basic research in the natural sciences, life sciences, social sciences, and the arts and humanities. They have a total staff of approximately 24,000 permanent employees, including 15,000 scientists, and around 5,000 non-tenured scientists and guests. As of December 31, 2018, the proportion of female employees was 44.4 percent. The Max Planck Society (with its 86 Max Planck Institutes) has a world-leading reputation as a science and technology research organization, with more than 33 Nobel Prizes awarded to its scientists, and is widely regarded as one of the foremost basic research organizations in the world.

Canji, Inc., part of Merck & Co., Inc., is a company headquartered in San Diego, CA, specializing in medical laboratories. Schering-Plough Corp., now part of Merck & Co., Inc. acquired Canji, Inc. on February 02, 1996 for $54.50 million.

Manufactures pharmaceuticals

Five3 Genomics, LLC offers cancer genome data processing services. The company provides genome processing services for researchers including alignment, mutational calling, rearrangement detection, and copy number estimation. It caters to research, biotech, and patient care sectors. Five3 Genomics, LLC is based in Santa Cruz, California.

CAVΛDIS™ is a Dutch biomedical company active in the field of cardiovascular risk assessment. They develop prognostic tests to identify patients at risk of cardiovascular and disease. The company identified several novel biomarkers predictive for cardiovascular events. It is their goal is to develop clinically meaningful risk stratification tools that will help personalize treatment and achieve better patient outcomes.

NHC Communications, Inc. manufactures network switching and test equipment for local telecom service providers, corporations and multi-tenant buildings. It also offers the XPoint product line geared for smaller network applications. The company was founded in 1986 and is headquartered in Mount-Royal, Canada

Hera Testing Laboratories develops preclinical drugs for vivo and vitro toxicology. The company's line of business includes providing professional analytic and diagnostic services for the medical profession.